Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an update.
CanSino Biologics Inc. has established a Remuneration and Assessment Committee to enhance its corporate governance structure. This committee is responsible for evaluating the performance and remuneration of directors and senior management, which is expected to improve transparency and accountability within the company.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in the People’s Republic of China. It focuses on the development and commercialization of innovative vaccines for various infectious diseases, aiming to address global health challenges.
Average Trading Volume: 2,081,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.13B
See more data about 6185 stock on TipRanks’ Stock Analysis page.